December 26, 2016
Ono Pharmaceutical said on December 22 that it has inked a worldwide license accord with Ligand Pharmaceuticals for the use of the US biotech’s three transgenic animal platforms for producing human therapeutic antibodies dubbed “OmniAb.” The deal allows Ono to...read more